Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends. - Wikidata - awgldk - TriplyDB

Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.

Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.

http://www.wikidata.org/entity/Q37725973

about

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.

P2860

Q35989963-3B4CE510-04D1-4162-9388-F3CD4D1C40DA

P2860

Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.

http://www.wikidata.org/entity/Q37725973

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Management of metastatic HER2- ...... nt evidence and future trends.

@en

Management of metastatic HER2- ...... nt evidence and future trends.

@nl

type

label

Management of metastatic HER2- ...... nt evidence and future trends.

@en

Management of metastatic HER2- ...... nt evidence and future trends.

@nl

prefLabel

Management of metastatic HER2- ...... nt evidence and future trends.

@en

Management of metastatic HER2- ...... nt evidence and future trends.

@nl

P1433

Q37725973-D0220750-44BE-4EAE-988C-CAC813CB1AAF

P1476

Q37725973-85C2FF0D-7AAE-43F1-BA71-A7E9615FA02B

P2093

Q37725973-0C2FAC64-53E0-4D76-AF9F-2986B679350C

Q37725973-9FE7FAC0-DF09-42EB-A7A5-9D5405C2ED55

Q37725973-C006CD30-C097-465D-9B07-9564D56D47A1

P2860

Q37725973-01021BF7-59DB-4184-8958-3BA57866C88A

Q37725973-0CF49043-F004-4961-8FEB-F3106229E37F

Q37725973-0F0005E5-49BC-47A0-B3ED-64B9B2FD9AE4

Q37725973-1801EFC4-32A9-4B2B-9096-9F6DB590A709

Q37725973-182ACB62-E60B-4F7C-9A9B-C10047F5E06F

Q37725973-1EAB8650-42EC-45AD-A57B-C3D2BA823FC3

Q37725973-1ED7566D-FECA-4DFE-ACAE-BAAA4D4FCB07

Q37725973-28886172-203C-441D-9365-37F366FE1F4D

Q37725973-2A6F1E13-5337-4802-AEB9-56C484DCE85B

Q37725973-2C693AE9-5D6F-4F36-A642-60A70312189A

P304

Q37725973-30C52111-E655-4681-ACE8-2C1DB3890FE4

P31

Q37725973-22D276C4-C8A8-465E-8767-0F7C0A4400AD

P356

Q37725973-E31E059F-A3F9-4AA0-A980-C704202EA953

P407

Q37725973-A2B0B216-CE1F-44C9-AFBC-A9118613E9ED

P478

Q37725973-8E1020FF-9302-4FFB-B0CA-01F62EB1A5D3

P577

Q37725973-90D188CD-01BD-4554-91AA-A6D0FB2CF50A

P698

Q37725973-C830E1B5-BEE4-48F5-BFCD-F3CBDD497333

P356

13543781003730135

P1433

Expert Opinion on Investigational Drugs

P1476

Management of metastatic HER2- ...... nt evidence and future trends.

@en

P2093

Ahmad Awada

http://www.w3.org/2001/XMLSchema#string

Otto Metzger-Filho

http://www.w3.org/2001/XMLSchema#string

Tushar Vora

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

P304

S31-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543781003730135

http://www.w3.org/2001/XMLSchema#string

P407

P478

19 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20374028

http://www.w3.org/2001/XMLSchema#string